Evidence map›Paper›PMID 30446580›Full record

ArticleCold Spring Harbor molecular case studies2018

Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma.

Jenny J Ko, Jasleen K Grewal, Tony Ng, Jean-Michel Lavoie, My Linh Thibodeau, Yaoqing Shen, Andrew J Mungall, Greg Taylor, Kasmintan A Schrader, Steven J M Jones and 3 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jenny J KoSystemic Therapy, BC Cancer - Abbotsford, Abbotsford, British Columbia V2S 0C2, Canada.ORCID 0000-0002-9286-2673
Jasleen K GrewalCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Tony NgDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, British Columbia V5Z 1M9, Canada.
Jean-Michel LavoieSystemic Therapy, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
My Linh ThibodeauCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Yaoqing ShenCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Greg TaylorCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Kasmintan A SchraderHereditary Cancer Program, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Christian KollmannsbergerSystemic Therapy, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
Janessa LaskinSystemic Therapy, BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.
Canada's Michael Smith Genome Sciences Centre · CABC Cancer Agency · CAAbbotsford Veterinary Clinic · CAVancouver General Hospital · CA

Funding

CIHR FDN-143288
6 · The paper itself

Abstract

Thyroid-like follicular renal cell carcinoma (TLFRCC) is a rare cancer with few reports of metastatic disease. Little is known regarding genomic characteristics and therapeutic targets. We present the clinical, pathologic, genomic, and transcriptomic analyses of a case of a 27-yr-old male with TLFRCC who presented initially with bone metastases of unknown primary. Genomic DNA from peripheral blood and metastatic tumor samples were sequenced. A transcriptome of 280 million sequence reads was generated from the same tumor sample. Tumor somatic expression profiles were analyzed to detect aberrant expression. Genomic and transcriptomic data sets were integrated to reveal dysregulation in pathways and identify potential therapeutic targets. Integrative genomic analysis with The Cancer Genome Atlas (TCGA) data set revealed the following outliers in gene expression profiles:

Indexed as

Adenocarcinoma, FollicularAdultBiomarkers, TumorCarcinoma, Renal CellGene Expression ProfilingGenomeGenome-Wide Association StudyGenomicsHumansMaleMutationNeoplasm MetastasisNeoplasmsReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaSunitinibBiomarkers, TumorReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaSunitinibmalignant genitourinary tract tumorrenal neoplasm

Identifiers

PMID30446580
PMCPMC6318773
OpenAlexW2900877533

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.